Alzheimer's Disease News and Research

RSS

Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.

Bristol-Myers Squibb to review key accomplishments at meeting with investment community

During a meeting with the investment community today, Bristol-Myers Squibb Company will provide a comprehensive business overview, highlight positive pipeline developments and provide 2013 minimum non-GAAP earnings per share guidance.

5 Mar 2010

2010 Federal Budget lacks substantive funding in support of heart health initiatives: HSF concerned

The Heart and Stroke Foundation (HSF) is concerned with the lack of any substantive funding in support of heart health initiatives as outlined in today's 2010 Federal Budget.

5 Mar 2010

Isotechnika Pharma receives grant of $237,069 to support NICAM program

Isotechnika Pharma Inc. today announced that it has received funding approval from the National Research Council's Industrial Research Assistance Program (IRAP) for its Non-Immunosuppressive Cyclosporin Analog Molecules (NICAM) program.

5 Mar 2010

Beneficial Alzheimer's therapies, update on prevention efforts focused at ADI International Conference

Beneficial Alzheimer's therapies that don't use drugs, and an update on prevention efforts, are the focus of the second day's plenary sessions at the 25th International Conference of Alzheimer's Disease International, March 12, 2010 at the Grand Hotel Palace, Thessaloniki, Greece.

4 Mar 2010

25th Alzheimer's Disease International conference: Focus on new treatment developments

"What's new" in Alzheimer's disease medical treatments and diagnosis is the focus of the first day's plenary sessions at the 25th International Conference of Alzheimer's Disease International (ADI), March 11, 2010 at the Grand Hotel Palace, Thessaloniki, Greece.

4 Mar 2010

Brain study may lead to new forms of treatment for Alzheimer's disease

A study from EPFL's (Ecole Polytechnique F-d-rale de Lausanne) Laboratory of Neuroenergetics and Cellular Dynamics in Lausanne Switzerland, published today in the Journal of Neuroscience, may lead to new forms of treatment following a better understanding of how Amyloid-Beta found in cerebral plaques, typically present in the brain of Alzheimer's patients, may lead to neurodegeneration.

4 Mar 2010

Failure of Alzheimer's drug Dimebon: Anavex Life Sciences comments

Anavex Life Sciences Corp. today issued a statement following today's announcement from Pfizer and Medivation (MDVN) that their investigational Alzheimer's drug Dimebon did not meet either its co-primary or secondary endpoints compared to placebo during pivotal Phase 3 clinical trials.

4 Mar 2010

New chemical classes of preclinical compounds identified for Alzheimer’s disease

In an announcement today, Mount Sinai School of Medicine and Medisyn Technologies, Inc. said they have identified new chemical classes of preclinical compounds that may eventually lead to the first effective management of toxic amyloid aggregation and accumulation in the brain— an abnormal biological process long suspected by many researchers to be a major culprit in the onset and progression of Alzheimer’s disease.

4 Mar 2010

Negative results from latrepirdine Phase III clinical trial: Alzheimer's Association disappointed

"The Alzheimer's Association is disappointed to learn of the negative results from the Phase III clinical trial of latrepirdine (Dimebon)," said William Thies, Ph.D., Alzheimer's Association Chief Medical and Scientific Officer. "People with Alzheimer's, their families and caregivers desperately need more and better treatment options for this devastating, fatal brain disease."

4 Mar 2010

Study indicates ocular shingles may increase stroke risk

Having a shingles infection that affects the eyes may increase the risk of stroke, according to new research published in the March 3, 2010, online issue of Neurology®, the medical journal of the American Academy of Neurology.

4 Mar 2010

NAEC elects Mayo Clinic as top epilepsy treatment center

Mayo Clinic has been designated a comprehensive epilepsy treatment center by the National Association of Epilepsy Centers (NAEC). Only the top epilepsy programs - those that can provide the most complex and advanced care - are selected for this designation, according to the association.

3 Mar 2010

Researchers launch new project to diagnose and treat dementia among Deaf people who use BSL

Researchers have launched a unique project to improve early diagnosis and management of dementia among Deaf people who use British Sign Language (BSL).

From The University of Manchester 3 Mar 2010

Pfizer, Medivation announce results of two dimebon Phase 3 trials in AD patients

Pfizer Inc. and Medivation, Inc. today announced results from two Phase 3 trials of the investigational drug dimebon (latrepirdine) in patients with Alzheimer’s disease (AD). In the CONNECTION trial, dimebon did not meet its co-primary or secondary efficacy endpoints compared to placebo. Co-primary endpoints were measures of cognition and global function.

3 Mar 2010

Investigators use ANNs to recognize risk factors of AD in patients with MCI

Mild cognitive impairment (MCI) is often considered an early symptom of Alzheimer's disease (AD). An analysis of genetic risk factors predisposing to MCI is critical for accessing individual predisposition and reliably evaluating the effectiveness of early treatment. In a groundbreaking study published in the February 2010 issue of the Journal of Alzheimer's Disease investigators successfully used artificial neural networks (ANNs) to help understand the causal relation between multiple factors and the occurrence of neurodegenerative disorders.

3 Mar 2010

Pioneering stem cell research could revolutionize treatments for diabetes and Alzheimer's disease

A heart patient's own skin cells soon could be used to repair damaged cardiac tissue thanks to pioneering stem cell research of the University of Houston's newest biomedical scientist, Robert Schwartz.

3 Mar 2010

Sea squirts help in fight against Alzheimer's disease

Alzheimer's disease affects an estimated 27 million people worldwide. It is the most common form of age-related dementia, possibly the most feared disease of old age. There is no cure, and the available drugs only help to relieve symptoms without slowing progression of the disease. One of the characteristic changes in the brains of Alzheimer's patients is the accumulation of plaques and tangles; currently, the best hope for curing or at least slowing the disease lies in developing drugs that target this buildup.

2 Mar 2010

Clot-busting drug therapy after stroke beneficial for women

New research shows women who don't receive a clot-busting drug after a stroke fare worse than men who are not treated. The study is published in the March 2, 2010, print issue of Neurology®, the medical journal of the American Academy of Neurology.

2 Mar 2010

Causal relation between multiple factors and occurrence of neurodegenerative disorders: ANNs help understand better

2 Mar 2010

Individuals having greater purpose in lives less likely to develop Alzheimer's disease: Study

Individuals who report having greater purpose in their lives appear less likely to develop Alzheimer's disease or its precursor, mild cognitive impairment, according to a report in the March issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

2 Mar 2010

$28M grant to examine neural and behavioral profiles of healthy cognitive aging

The Research Partnership in Cognitive Aging, a public-private effort to promote the study of brain function with age, will award up to $28 million over five years to 17 research grants to examine the neural and behavioral profiles of healthy cognitive aging and explore interventions that may prevent, reduce or reverse cognitive decline in older people.

2 Mar 2010

Alzheimer's Disease News and Research

Further Reading

Bristol-Myers Squibb to review key accomplishments at meeting with investment community

2010 Federal Budget lacks substantive funding in support of heart health initiatives: HSF concerned

Isotechnika Pharma receives grant of $237,069 to support NICAM program

Beneficial Alzheimer's therapies, update on prevention efforts focused at ADI International Conference

25th Alzheimer's Disease International conference: Focus on new treatment developments

Brain study may lead to new forms of treatment for Alzheimer's disease

Failure of Alzheimer's drug Dimebon: Anavex Life Sciences comments

New chemical classes of preclinical compounds identified for Alzheimer’s disease

Negative results from latrepirdine Phase III clinical trial: Alzheimer's Association disappointed

Study indicates ocular shingles may increase stroke risk

NAEC elects Mayo Clinic as top epilepsy treatment center

Researchers launch new project to diagnose and treat dementia among Deaf people who use BSL

Pfizer, Medivation announce results of two dimebon Phase 3 trials in AD patients

Investigators use ANNs to recognize risk factors of AD in patients with MCI

Pioneering stem cell research could revolutionize treatments for diabetes and Alzheimer's disease

Sea squirts help in fight against Alzheimer's disease

Clot-busting drug therapy after stroke beneficial for women

Causal relation between multiple factors and occurrence of neurodegenerative disorders: ANNs help understand better

Individuals having greater purpose in lives less likely to develop Alzheimer's disease: Study

$28M grant to examine neural and behavioral profiles of healthy cognitive aging

Aneuro: A Year of Neuroscience in Review eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News